Calm Waters Partnership
—- Market cap
- —
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: Calm Waters Partnership stock price vs BMY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMY's multiple
Needs Annual EPS.
Implied fair value · at Calm Waters Partnership's multiple
Needs Calm Waters Partnership P/E.
Engine logicCalm Waters Partnershipvalued onBMY’smultiple
Metric by metric
Snapshot Sep 8, 2026, 4:00 PM ET
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: Calm Waters Partnership Latest annual filing · BMY FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 74% equity / 26% debt · EV / Revenue 3.51x · EV / EBITDA 10.87x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CALM WATERS PARTNERSHIP · implied price per share
Reporting currency could not be verified.
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$59.11
Base
$72.93
Bull
$92.88
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Calm Waters Partnership · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
2.55x
Net debt / EBITDA
Leverage against operating earnings
—
2.37x
Cash and equivalents
Liquid reserves on the balance sheet
—
$10.21B
Total debt
Interest-bearing obligations outstanding
—
$47.09B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
Calm Waters Partnership vs PFE
Merck & Co., Inc.
Calm Waters Partnership vs MRK
AbbVie Inc.
Calm Waters Partnership vs ABBV
Eli Lilly and Company
Calm Waters Partnership vs LLY
Amgen Inc.
Calm Waters Partnership vs AMGN
Gilead Sciences, Inc.
Calm Waters Partnership vs GILD
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.